Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión) Open Journal Systems
Dosis de enoxaparina asociada a disminución de riesgo de muerte en COVID-19 / Enoxaparin dose associated with decreased risk of death in COVID-19
Resumen
Resumen
Introducción: en diciembre de 2019 se reportó por primera vez un brote de COVID-19. Esta enfermedad ha ocasionado millones de muertes a nivel mundial. A la fecha se han probado multiples fármacos, sin encontrar un tratamiento eficaz aún.
Objetivo: describir la evolución y el tratamiento farmacológico utilizado en pacientes hospitalizados por COVID-19.
Material y métodos: estudio observacional en 200 pacientes hospitalizados por COVID-19 en un hospital regional de Acapulco que ingresaron entre marzo y julio de 2020. Se identificaron las características, el tratamiento farmacológico y la evolución de los pacientes. Se realizó analisis univarido, bivariado y multivariado.
Resultados: el 60% de los pacientes fueron del sexo masculino, 83% presentaron al menos una comorbilidad, 56% fallecieron. El fármaco más utilizado fue la enoxaparina, del cual recibir dosis de 60 mg se asoció a menor riesgo de fallecer comparado con recibir 40 mg. Haber recibido hidroxicloroquina, metilprednisolona, moxifloxacino y tener 60 años o más se asoció a un mayor riesgo de morir.
Conclusiones: se presentó una elevada mortalidad. El fármaco más utilizado fue la enoxaparina, del cual utilizar dosis de 60 mg disminuyó el riesgo de fallecer.
Abstract
Background: In December 2019, an outbreak of COVID-19 was reported for the first time. This disease has caused millions of deaths worldwide. To date multiple drugs have been tried, without finding an effective treatment yet.
Objective: To describe the evolution and the pharmacological treatment used in patients hospitalized due to COVID-19.
Material and methods: Observational study in 200 patients hospitalized due to COVID-19 in a regional hospital of Acapulco who were admitted between March and July 2020. The characteristics, pharmacological treatment and evolution of the patients were identified. Univariate, bivariate and multivariate analyses were performed.
Results: 60% of the patients were male, 83% had at least one comorbidity, 56% died. The most used drug was enoxaparin, of which receiving a 60 mg dose was associated with a lower risk of death, compared to receiving 40 mg. Having received hydroxychloroquine, methylprednisolone, moxifloxacin and being 60 years or older was associated with a higher risk of progressing to death.
Conclusions: There was a high mortality. The most used drug was enoxaparin, of which using doses of 60 mg reduced the risk of death.
Palabras clave
Texto completo:
PDFReferencias
Zhu N, Zhang D, Wang W, X Li, Yang B, Song J, et al; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. doi:10.1056/NEJMoa2001017.
Organización Panamericana de la Salud. COVID-19 Daily Update: 26 May, 2021. Disponible en https://www.paho.org/ en/documents/paho-covid-19-daily-update-26-may-2021 [consultado el 26 de mayo de 2021].
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324(8):782-93. doi:10.1001/jama.2020.12839.
Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19) [Updated 2021 Apr 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. Disponible en https://www.ncbi.nlm.nih.gov/books/NBK554776/
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;323(18):1824-36. doi:10. 1001/jama.2020.6019.
Watanabe JH, Kwon J, Nan B, Abeles SR, Jia S, Mehta SR. Medication Use Patterns in Hospitalized Patients With COVID-19 in California During the Pandemic. JAMA Netw Open. 2021;4(5):e2110775. doi:10.1001/jamanetworkopen. 2021.10775.
Ledford H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature. 2020;582(7813):469. doi: 10.1038/d41586-020-01824-5.
RECOVERY Collaborative Group. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. University of Oxford; 16 June 2020.
RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021; 384:693-704. doi: 10.1056/NEJMoa2021436.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020;395 (10236):1569-78.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383(19):1813-26.
Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for hospitalized adults with Covid-19. N Engl J Med. https://doi.org/10.1056/ NEJMoa2031994 (2020).
Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120-128. doi:10.1056/NEJMoa2015432.
Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020;173(4):268-77. doi:10.7326/ M20-2003.
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al.; Global COVID-19 Thrombosis Collaborative Group. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and followup: jacc state-of-the-art review. J Am Coll Cardiol. 2020;75 (23):2950-73. doi:10.1016/j.jacc.2020.04.031.
Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020;41(32):3038-3044. doi:10.1093/ eurheartj/ehaa623.
Jiménez D, García-Sanchez A, Rali P, Muriel A, Bikdeli B, Ruiz-Artacho P, et al. Incidence of venous thromboembolism and bleeding among hospitalized patients with COVID-19: a systematic review and meta-analysis. Chest. 2021;159(3): 1182-96. doi:10.1016/j.chest.2020.11.005.
Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA. 2020;324 (8):799-801. doi:10.1001/jama.2020.13372.
López-Reyes R, Oscullo G, Jiménez D, Cano I, GarcíaOrtega A. Thrombotic Risk and Covid-19: Review of Current Evidence for a Better Diagnostic and Therapeutic Approach. Arch Bronconeumol. 2021;57:55-64.
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Disponible en https://www.covid19treatmentguidelines. nih.gov/
Instituto Mexicano del Seguro Social. Algoritmos interinos para la atención del COVID-19. Actualización del 14 de Septiembre del 2020. Disponible en http://educacionensalud.imss.gob.mx/ es/system/files/Algoritmos_interinos_COVID19_CTEC.pdf.
Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA Intern Med. 2020;180(11):1436-47. doi:10.1001/jamainternmed.2020.3596.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. doi:10.1001/jama.2020.1585.
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-81. doi:10.1016/S2213-2600(20)30079-5.
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al.; COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574-81. doi:10.1001/jama.2020.5394.
RECOVERY Collaborative Group. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 Nov 19;383(21):2030-40.
Zhang R, Mylonakis E. In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon β-1a differed from standard care for in-hospital mortality. Ann Intern Med. 2021;174(2):JC17.
Ranjbar K, Moghadami M, Mirahmadizadeh A, Fallahi MJ, Khaloo V, Shahriarirad R, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis. 2021;21(1):337. doi: 10.1186/s12879-021-06045-3.
Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial. Clin Infect Dis. 2021 May 4;72(9):e373-81. doi: 10.1093/ cid/ciaa1177.
Xi WN, Jin D, Sun K, Yu RY, Yao XB, Zou BS, et al. Treatment with Arbidol and Moxifloxacin in Ordinary and Severe Adult Patients Infected with COVID-19. 2020. doi:10.1101/2020.05.30.20117598.
Drago F, Gozzo L, Li L, Stella A, Cosmi B. Use of enoxaparin to counteract COVID-19 infection and reduce thromboembolic venous complications: A review of the current evidence. Front Pharmacol. 2020;11:579886.
Paolisso P, Bergamaschi L, D’Angelo EC, Donati F, Giannella M, Tedeschi S, et al. Preliminary experience with low molecular weight heparin strategy in COVID-19 patients. Front Pharmacol. 2020;11:1124.
Ugur M, Adiyeke E, Recep E, Bakan N, Yiyit N. Aggressive thromboprophylaxis improves clinical process and decreases the need of Intensive Care Unit in Covid-19. Pak J Med Sci Q [Internet]. 2021;37(3). Disponible en http://pjms.org.pk/index. php/pjms/article/view/3687.
Albani F, Sepe L, Fusina F, Prezioso C, Baronio M, Caminiti F, et al. Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARSCoV-2 infection. A cohort study. EClinicalMedicine. 2020;27 (100562):100562.
INSPIRATION Investigators. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA. 2021;325(16):1620-30. doi:10.1001/ jama.2021.4152.
Enlaces refback
- No hay ningún enlace refback.